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Abstract 
Background   Evaluation of antibiotic-impregnated  (AI) and ionized silver particle coated external 
ventricular drainage catheters (EVD) in patients with subarachnoid (SAH) or intracranial hemorrhage 
(ICH). 
Methods Between February 2011 and June 2012, 40 patients with acute hydrocephalus due to SAH, 
ICH or intraventricular hemorrhage were enrolled in a prospective, randomized, mono-center pilot 
study. Primary endpoints were defined as: number of events of cerebrospinal fluid (CSF) infections. 
Secondary endpoints were defined as: neurosurgical complications following the placement of the 
EVD, number of revisions of EVD catheters, and cost effectiveness. 
Results Sixty-one EVD placements in 40 patients, 32 antibiotic-coated (Bactiseal®), 29 silver-bearing 
catheters (VentriGuard®), have been performed. Confirmed or high suspicion of CSF infections 
occurred in 11 out of 61 events (confirmed   infection:    p = 0.71,    probable    infection: p = 0.90). 
Revisions of EVD were needed in 13 cases (22 %) due to CSF infection, dysfunction, impaired 
healing, or malplacement (p = 0.37). 
Conclusion   Regarding CSF infection rate and dysfunc- tion, no statistical significant differences 
between the two EVD catheters Bactiseal® versus VentriGuard® were found. The silver-bearing 
catheter might offer a safe and cost-conscious alternative to the AI catheter. 
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Introduction 
The placement of external ventricular drainage catheters (EVD) belongs to the standard surgical 
procedures in managing acute hydrocephalus [1–3]. Perioperative complications, however, such as 
infections, intracranial hemorrhages (ICHs), or catheter malplacements are well known [3, 4]. 
Several previous trials have focused on catheter related cerebrospinal fluid infections (CSF) and 
bacterial colonization due  to  different  types  of  EVDs (0–27 %), [4–7]. 
Zabramski et al. [6] and Abba et al. [7] reported about the efficacy of EVD polyethylene catheters 
impregnated with rifampicin and clindamycin versus non-coated cathe- ters.  Antibiotic-coated 
catheters  (AI)  have  shown decreased colonization and CSF infection rates [6, 7]. Recently, 
however, Pople et al. presented an international, prospective, randomized, open label trial indicating 
low infection  rates  in  both  study  arms,  i.e.,  AI  catheters (17.6 %) versus standard EVD (20.4 
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%). Furthermore, AI catheters were not associated with a lower infection rate compared to non-
coated catheters [8]. 
In retrospective trials, Lackner and Fichtner et al. ana- lyzed the efficacy of the silver-impregnated 
EVD catheters (SI) versus non-coated EVD. Both studies showed a sig- nificant reduction of 
bacterial colonization and CSF infection rate in the SI group (18.9 %) [9, 10]. Keong et al. reported 
in a double-blinded, prospective, randomized controlled trial a significant difference in infection 
rate between the two study arms (non-coated: 21.4 % vs. silver- bearing: 12.3 %, p = 0.04). They 
concluded that silver- bearing catheters reduce the risk of CSF infections [11]. 
At the University Hospital Zurich, Department of Neu- rosurgery, a prospective, randomized, mono-
center pilot study was established in order to evaluate antibiotic- impregnated (AI) versus ionized 
silver particle coated EVDs with regard to the incidence of CSF infections and neurosurgical 
complications following the placement of the EVD, as well as to the number of revisions of EVD 
cath- eters and the cost effectiveness. 
 
Patients and Methods 
From February 2011 to June 2012 a mono-centric, prospective randomized controlled trial to evaluate 
complications with AI versus silver-ionized EVD catheters was performed at the Department of 
Neurosurgery of the University Hospital Zurich (approved by the ethics committee: KEK-ZH-Nr: 
2010-214). Written informed consent was obtained from all participating patients. Primary endpoints 
were defined as: number of events of CSF infections. Secondary endpoints were defined as: 
neurosurgical complications following the placement of the EVD, number of revisions of EVD catheters, 
and cost effectiveness. 
 
 
Study Population 
 
Patients   between   18   and   80 years, admitted   to   the emergency unit with the initial diagnosis of 
subarachnoid hemorrhage (SAH), intracranial hemorrhage (ICH) or intraventricular hemorrhage, and 
occlusive hydrocephalus were randomized and enrolled. Exclusion criteria were: prior infections 
(meningitis, ventriculitis, sepsis, bacteriemia, chronic infection  disease,  or  skin  infection  close to 
the implantation site), allergic reactions to rifampicin or clindamycin, pregnancy or residency 
outside Switzerland. 
The two catheters examined were the AI ventricular drainage catheter (12 Charrier, 
Rifampicin/Clindamycin; Bactiseal®, Codman and Shurtleff, Johnson & Johnson, Ranyham, 
Massachusetts) and the silver-ionized (SI) ven- tricular drainage catheter (8.5 French, ionized, silver- 
bearing; VentriGuard®  Neuromedex, Zollikon Zurich, Switzerland). 
 
Treatment 
After randomization EVDs were placed according to a standardized insertion protocol [3]. CSF 
samples were collected during insertion and every third day thereafter and analyzed for leukocytes 
and microorganisms. Clinical signs of infection, such as fever, change of vigilance, and local wound 
control were documented. Detected microor- ganisms in the CSF and on the catheters were identified 
by direct microscopy and/or cultures performed by a blinded microbiologist (Department of 
Microbiology, University Hospital Zurich). CSF findings were categorized as fol- lows: CSF 
infection was assigned to be ‘‘confirmed’’ if the leukocyte count per visual field was >200 and 
clinical signs of CSF infection were present and microorganisms were identified in the CSF and/or 
the catheter tip. CSF infection was categorized as ‘‘probable’’ if the leucokyte count per visual field 
was >100 and/or one but not all of the characteristics above were present. Primary endpoints were 
the events of CSF and EVD infections. Secondary endpoints were surgical complications (impaired 
wound healing/CSF leakage, hemorrhage in trajectory, or mal- placement), changes of EVD, overall 
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costs of EVD, and identifying most common microorganisms in the CSF in cases of confirmed 
infection. 
 
Statistical Analysis 
 
We present numbers of patients and percentages of total for categorical    variables,    and    
continuous    variables    as mean ± standard deviation (SD). For the univariate com- parison of 
primary and secondary outcomes in the comparison groups AI-EVD and SI-EVD, we used v2 tests. 
Significance level a was set at 5 %. All analyses were performed with R (R Development Core Team 
2013. R: A language   and   environment   for   statistical   computing. R Foundation for Statistical 
Computing, Vienna, Austria). 
 
Results 
From February 2011 to June 2012 27 female (67 %) and 13 (33 %) male  patients, with the  mean age  
of  56.5 years (mean ± SD 13.2) were enrolled. 32 patients suffered from SAH (80 %), 8 from ICH 
(20 %). Twenty-eight patients with ruptured aneurysms were treated with clipping (8 patients) or 
coiling (20 patients), in 4 patients no aneurysm was detected in the angiography. In seven patients an 
ICH and in one patient an arteriovenous malformations was documented. Overall, 61 EVD catheters 
(32 Bactiseal vs. 29 VentriGuard) were placed in 40 patients. Mean time in situ was 15 days (range 3–
30 days). Duration of stay in the ICU was 27.6 ± 14.8 (mean ± SD).  The overall mortality rate was 16 
% (Tables 1, 2). 
 
Primary Endpoint 
 
CSF  infections  (including  categories  ‘‘confirmed’’  and ‘‘probable’’) occurred in a total of 11 out 
of 61 events (18 %),  3  confirmed with  AI  and  3  confirmed with  SI catheters  (10 %,  p = 0.71),  2  
probable  with  AI  and  3 probable with SI catheters (8 %, p = 0.90). Median onset of infection was 
day 11 (range 5–30 days). In confirmed infections the microbiological examinations revealed 
Staphylococcus coagulase negative (in total 4 events; 2 events with AI and 2 events with SI catheters) 
and Escherichia coli (in total 2 events; 1 with AI and with SI catheters) (Table 3). 
 
Secondary Endpoint 
 
Overall revisions of EVD were necessary in 13 cases (22 %, p = 0.37). In three patients (a 
hemorrhage in the trajectory line (2 patients with AI, 1 with SI catheters, 5 %, p = 0.51) and in two 
patients a malplacement of the EVD (with AI catheter) occurred (3 %, p = 0.93). No allergic 
reactions occurred in either of the groups. In 12 patients (30 %) ventricular peritoneal shunt 
placement (VP-shunt) was performed later on. Overall costs of EVD devices were 
20.345 USD (5.103 USD higher in the AI group) (Table 4). 
 
 
Discussion 
The present pilot study in 40 patients revealed equal rates of CSF infection in patients with AI 
compared to patients with SI catheters. With six (10 %) confirmed and  five (8 %) probable 
infections, the overall infection rate was comparable with previous published data [3, 4, 6, 8, 9, 11]. 
 
Lozier and colleagues [12, 13] analyzed a cumulative CSF infection rate of 8.8 % (range 2.2–21.9 
%) in 23 studies. A very low proven infection rate (2.5–2.8 %) was recently reported by Pople et 
al. [8], though the rate was influenced by abundant use of antibiotics and based on primary EVD 
placements only. The silver trial of Keong et al. [11] with an infection rate of 12.3 % showed more 
comprehensible results. Our patient population represented a group of most severely ill patients with 
long ICU stays, consecutive high risks of infections and complications as well as revisionary and 
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secondary EVD placements.  Antibiotics were used only if systemic infections or proven, 
respectively, proba- ble CSF infections were detected. Onset of infection or length of implantation 
did not influence the infection rate in our population. However, data on the comparison of AI 
versus SI catheters have not been published yet. 
Bacterial resistance and allergic reactions, especially seen in colonization with Staphylococcus 
aureus in rif- ampicin and clindamycin coated catheters, are still under discussion in the literature 
[4]. Furthermore, observations of neurotoxicity of silver ions have been described [14]. However, 
no allergic reactions were reported in either of the groups and no evident neurotoxic side effects of 
silver particles were observed in the group with SI catheters. 
The overall surgical complication rate of 7 % (Table 1) fits in the lower median as reported in 
literature (range 1–33 %) [3, 15, 16]. Following a retrospective evaluation of surgical complication 
rates at the Department of Neu- rosurgery of the University Hospital Zurich [3], a standardized 
surgical and handling protocol was estab- lished which enabled to reduce the surgical complication 
rate from 10 to 7 %.  Therefore, standardized surgical protocols and thoroughly maintained EVD 
devices improve the surgical and overall complication rate and should be established in every center 
[3, 5, 8, 11–13, 15, 16]. 
Handling and maintenance of AI or SI catheters in ICU were standardized and showed no difference 
in either group. From an economic and diagnose related group point of view, it seems that the SI 
catheter is more cost-efficient than the AI catheter (Table 4). 
Although the caseload of this prospective, randomized, mono-center pilot study is limited, our 
preliminary data suggest that there is no difference between the AI or SI catheters in this selected 
patient population. 
 
Conclusion 
This is the first prospective, randomized, mono-center pilot study to evaluate the incidence of CSF 
infections after placement of AI versus silver-ionized ventricular drainage catheters. No significant 
differences between the two EVD catheters, especially regarding the CSF infection rate, were found. 
The silver-ionized catheter might be a safe and cost- conscious alternative to the AI catheter. To 
underline these observations, further multicenter randomized trials would be needed. 
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Variables 
 
Gender 
Category 
 
Male: n = 13 
Percentage 
 
33 
  Female: n = 27 67 
Age (mean ± SD, y) 
Admission disease 
56.5 ± 13.2 
SAH: n = 32 80 
  AVM: n = 1 3 
  ICH: n = 7 17 
Days in ICU (mean ± SD) 
Glasgow outcome scale 
27.6 ± 14.8 
1: n = 6 15 
  2: n = 0 0 
  3: n = 3 7.5 
  4: n = 9 22.5 
  5: n = 22 55 
WFNS  
1 4 
2 9 
3 3 
4 5 
5 11 
Table 1 
Patient characteristics, severity measures and outcome scores 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SD standard deviation, y years 
ICU intensive care unit 
SAH subarachnoid haemorrhage 
AVM arterio-venous malformation, 
ICH intracranial haemorrhage 
 
 
 
Table 2 
Scores by reason for admission 
 
 
 Reason for admission 
 
 SAH (n = 32) AVM (n = 1) ICH (n = 7) 
 
 
 
 
 
 
 
 
 
Hunt + Hess 
1 2 
2 15 
3 5 
4 5 
5 5 
Fisher 
1 0 
2 1 
3 14 
4 16 
GCS 
3   1 
8–3  1  4 
15-8  2 
 
 
WFNS World Federation of Neurosurgeons 
GCS Glasgow coma scale 
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Table 3  Primary endpoints: CSF infections 
 
Characteristics Overall (n) AI-EVD (n) SI-EVD (n) p* 
EVD 61 32 29 – 
CSF infection 11 5 6 0.92
Confirmed inf. 6 3 3 0.71
Probable inf. 
Onset of CSF 
5 
11 (d, median) 
2 
– 
3 
– 
0.90
 
n number, AI-EVD antibiotic external ventricular drainage catheter, SI-EVD silver-ionized external ventricular 
drainage catheter, CSF cere- brospinal fluid, inf infection, d day 
* p value from v2  test 
 
 
Table 4 Secondary endpoints: revision, surgical complications, costs 
  
Characteristics Overall (n) AI-EVD (n) SI-EVD (n) p* 
Revision 13 5 8 0.37
Malplacement 2 1 1 0.51
Hemorrhage 3 2 1 0.93
Costs (USD) 20.345 – –  
Difference in costs (USD)  +5.103   
n number, AI-EVD antibiotic external ventricular drainage catheter, SI-EVD silver-ionized external ventricular drainage 
catheter, USD US Dollar 
* p value from v2  test 
 
 
 
 
 
 
References 
 
1. van Gijn J, Hijdra A, Wijdicks EF, Vermeulen M, van Crevel H. Acute hydrocephalus after 
 aneurysmal subarachnoid hemorrhage. J Neurosurg. 1985; 63: 355–62. 
2. Hasan D, Vermeulen M, Wijdicks EF, Hijdra A, van Gijn J. Management problems in acute 
 hydrocephalus after subarachnoid hemorrhage. Stroke. 1989; 20: 747–53. 
3. Woernle CM, Burkhardt JK, Bellut D, Krayenbuehl N, Bertalanffy H. Do iatrogenic factors bias 
 the placement of external ventricular catheters?—a single institute experience and review of 
 the literature. Neurol Med Chir (Tokyo). 2011; 51(3): 180–6. 
4. Scheithauer S, Burgel U, Ryang YM, Koch S, Schiefer J, Hafner H, Haase G, Lemmen SW. 
 Prospective surveillance of drain- associated meningitis/ventriculitis in a neurosurgery and a 
 neu- rologic intensive care unit. J Neurol Neurosurg Psychiatry. 2009; 80(12): 1381–5. 
5. Hoefnagel D, Dammers R, Ter Laak-Poort MP, Avezaat CJ. Risk factors  for  infections related  
 to  external  ventricular  drainage. Acta Neurochir (Wien). 2008; 150:209–14; discussion 214. 
6. Zabramski JM, Whiting D, Darouiche RO, Horner TG, Olson J, Robertson C, Hamilton AJ. 
 Efficacy of antimicrobial-impreg- nated external ventricular drain catheters: a prospective, 
 randomized, controlled trial. J Neurosurg. 2003; 98(4):725–30. 
7. Abla AA, Zabramski JM, Jahnke HK, Fusco D, Nakaji P. Comparison of two antibiotic-
 impregnated  ventricular catheters: a prospective sequential series trial. Neurosurgery. 
 2011; 68(2):437–42;  discussion 442. 
7 
 
8. Pople I, Poon W, Assaker R, Mathieu D, Iantosca M, Wang E, Zhang LW, Leung G, Chumas P, 
 Menei P, Beydon L, Hamilton M, Kamaly I, Lewis S, Ning W, Megerian JT, McGirt MJ, 
 Murphy JA, Michael A, Meling T. Comparison of infection rate with the use of antibiotic-
 impregnated vs standard extraventric- ular drainage devices: a prospective, randomized 
 controlled trial. Neurosurgery. 2012; 71(1):6–13. 
9. Fichtner J, Gu¨ resir E, Seifert V, Raabe A. Efficacy of silver-bearing external ventricular drainage 
 catheters: a retrospective analysis. J Neurosurg. 2010;  112(4):840–6. 
10. Lackner P, Beer R, Broessner G, Helbok R, Galiano K, Pleifer C, Pfausler B, Brenneis C, Huck 
 C, Engelhardt K, Obwegeser AA, Schmutzhard E. Efficacy of silver nanoparticles-
 impregnated external ventricular drain catheters in patients with acute occlu- sive 
 hydrocephalus. Neurocrit Care. 2008; 8(3):360–5. 
11. Keong N, Bulters D, Richards H, Farrington M, Sparrow O, Pickard J, Hutchinson P, Kirkpatrick 
 P. The SILVER (Silver- Impregnated Line Vs EVD Randomized) Trial: a double-blind, 
 prospective, randomized controlled trial of an intervention to reduce the rate of external 
 ventricular drain infection. Neuro- surgery. 2012; 71(2):394–403; discussion 403–4. 
12. Lozier AP, Sciacca RR, Romagnoli MF, Connolly ES Jr. Ven- triculostomy-related infections: 
 a critical review of the literature. Neurosurgery. 2002; 51(1):170–81; discussion 181–2. 
13. Le Roux AA, Wallace MC. Outcome and cost of aneurysmal subarachnoid hemorrhage. 
 Neurosurg Clin N Am. 2010; 21(2): 235–46 (Review). 
14. Lansdown AB. Critical observations on the neurotoxicity of silver. Crit Rev Toxicol. 2007; 
 37(3):237–50. 
15. Maniker AH, Vaynman AY, Karimi RJ, Sabit AO, Holland B. Hemorrhagic complications of 
 external ventricular drainage. Neurosurgery. 2006; 59:ONS419–24; discussion ONS24–5. 
16. Saladino A, White JB, Wijdicks EF, Lanzino G. Malplacement of ventricular catheters by 
 neurosurgeons: a single institution experience. Neurocrit Care. 2009; 10: 248–52. 
 
 
 
